Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hypertonic Saline for Outpatient Bronchiolitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by University Diego Portales.
Recruitment status was  Recruiting
Clínica Vespucio, Santiago, Chile
Information provided by:
University Diego Portales Identifier:
First received: June 9, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted

We will study if small children who become ill with respiratory distress during the RSV epidemic are better relieved with salbutamol nebulizations diluted in hypertonic (3%), instead of normal (0.9%) saline.

Condition Intervention Phase
Respiratory Distress
Drug: Inhalation of salbutamol diluted in hypertonic saline
Drug: Inhalation of salbutamol diluted in normal saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Hypertonic Vrs. Normal Saline as Diluent of Salbutamol to Reduce Respiratory Distress in Outpatients With the Clinical Diagnosis of Bronchiolitis During the RSV Epidemic.

Resource links provided by NLM:

Further study details as provided by University Diego Portales:

Primary Outcome Measures:
  • Change in the respiratory distress score (Tal) between the basal score and the final score after 3 salbutamol nebulizations [ Time Frame: 1 hour ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in the respiratory distress score (Tal) between the basal score and the first nebulization [ Time Frame: 15 to 20 minutes ] [ Designated as safety issue: No ]
  • Change in the respiratory distress score (Tal) between the basal score and the second nebulization [ Time Frame: 15 to 20 minutes after the first nebulization ] [ Designated as safety issue: No ]
  • Change in pulse oxymetry reading between the basal score and after each of the three nebulizations [ Time Frame: 1 hour ] [ Designated as safety issue: No ]
  • Change in cardiac frequency, irritability, general condition or anything else between the basal score and the first, second and third nebulization [ Time Frame: 1 hour ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 74
Study Start Date: June 2008
Estimated Study Completion Date: October 2008
Estimated Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Salbutamol is diluted in hypertonic (3%) saline.
Drug: Inhalation of salbutamol diluted in hypertonic saline
The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
Other Name: Albuterol diluted in hypertonic saline
Active Comparator: 2
Salbutamol is diluted in normal (0.9%) saline.
Drug: Inhalation of salbutamol diluted in normal saline
The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
Other Name: Albuterol diluted in normal saline

Detailed Description:

In Santiago, Chile, a near collapse of health services is a notorious feature of every winter when vast numbers of small children line for attention because of respiratory distress caused by a probable RSV infection.

Our study will examine if nebulized salbutamol diluted in hypertonic (3%), instead of normal (0.9%) saline, provides better relief in outpatients.

If hypertonic saline proves safe and effective, the patients could be better managed and the pressure for attention diminished at a low cost, by a simple change in the saline ampule.


Ages Eligible for Study:   1 Month to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 1 to 24 months
  2. Mild to moderate respiratory distress (Tal score below 9)
  3. Up to 5 days of respiratory symptoms, including today
  4. Expiratory wheezing heard on chest auscultation
  5. Indication of salbutamol nebulization treatment by attending physician

Exclusion Criteria:

  1. Two prior episodes of wheezing
  2. Premature birth (below 38 weeks), if below 6 months of age
  3. Lobar pneumonia
  4. Body temperature above 38 degree Celsius
  5. Use of salbutamol during the previous 6 hours
  6. Pulse oxymetry reading below 90%
  7. Congenital heart disease
  8. Chronic pulmonary disease: Asthma, cystic fibrosis, bronchopulmonary dysplasia
  9. Other chronic or genetic condition or disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00696540

Contact: Irmeli Roine, MD, PhD +56-2-6762916
Contact: Ricardo Mercado, MD +56-9-3320792

Clínica Vespucio Recruiting
Santiago, Chile, 00300
Contact: Ricardo Mercado, MD    +56-2-8206500   
Contact: Patricio Olivares, MD    +56-2-8206500   
Sponsors and Collaborators
University Diego Portales
Clínica Vespucio, Santiago, Chile
Principal Investigator: Irmeli Roine, MD, PhD University Diego Portales
Study Director: Ricardo Mercado, MD Clinica Vespucio, Santiago, Chile
  More Information

Responsible Party: Irmeli Roine, Facultad de Ciencias de la Salud, Universidad Diego Portales, Santiago. Chile Identifier: NCT00696540     History of Changes
Other Study ID Numbers: UDP-CT1-08
Study First Received: June 9, 2008
Last Updated: June 9, 2008
Health Authority: Chile: Instituto de Salud Pública de Chile

Keywords provided by University Diego Portales:
Bronchiolitis, respiratory distress, hypertonic saline

Additional relevant MeSH terms:
Bronchial Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Tract Diseases
Respiratory Tract Infections
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents processed this record on March 03, 2015